A Report on Global Illicit Drugs Markets 1998-2007

Total Page:16

File Type:pdf, Size:1020Kb

A Report on Global Illicit Drugs Markets 1998-2007 A Report on Global Illicit Drugs Markets 1998-2007 Full Report Editors: Peter Reuter (RAND) and Franz Trautmann (Trimbos Institute) http://ec.europa.eu www.trimbos.nl www.rand.org/randeurope • 12474-EC boek.indb 1 31-03-2009 09:57:15 This study has been produced by the Trimbos Institute and RAND with the financial support of the Commission of the European Communities (contract JLS/2007/C4/005). The study does not necessarily reflect the opinions and views of the European Commission, nor is it bound by its conclusions. More information on the European Union and drug policy can be found on the following website: http://ec.europa.eu/justice_home/fsj/drugs/fsj_drugs_intro_en.htm Cataloguing data can be found at the end of this publication. ISBN-13: 978-92-79-11945-3 © European Communities, 2009 • 12474-EC boek.indb 2 31-03-2009 09:57:16 Acknowledgements - A Report on Global Illicit Drugs Markets 1998-2007 Acknowledgements The authors would like to thank all people who contributed to this study. We owe a large debt to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Lisbon for the relevant input and support we received on many issues. The EMCDDA proved to be a particularly valuable source of information and expertise for our purposes. We want to express special thanks to Paul Griffiths, Brendan Hughes, Rosemary de Sousa and Frank Zobel who provided high quality information, data and advice throughout the project, as well as to their colleagues who contributed to specific sections in this report. We would like to express thanks to all the experts from the countries covered in the individual country reports in the Appendix. They took the time to answer all our questions and provided valuable information on drug problems and policy in their countries. We also would like to thank Jon Caulkins (Heinz School, Carnegie-Mellon University) for his useful comments and Jim Burgdorf (RAND) for his excellent research assistance to the Market Report. Thanks also to Greg Falconer and Philipp-Bastian Brutscher (RAND Europe) for their great assistance with the research for the economic cost report. Special thanks to the experts who made themselves available to review the draft report for their valuable input. The following experts gave input and precious suggestions for streamlining the final manuscript: Ruth Levitt (RAND), Wayne Hall (University of Queensland), Dick Hobbs (London School of Economics), Martin Bouchard (Simon Fraser University), William Rhodes (Abt Associates), Pierre Kopp (University of Paris-1), Michael Farrell (Institute of Psychiatry, London), Alison Ritter (University of New South Wales), and Louisa Degenhardt (University of New South Wales). We also would like to thank Henri Bergeron (Institut d’Etudes Politiques de Paris), Constantijn van Oranje-Nassau (RAND Europe) and Esther Croes (Trimbos Institute) for their helpful comments. Finally, many thanks to the people who gave precious support to get all things done: Toine Ketelaars (Trimbos Institute) for all the thorough literature searches, Yvonne Borghans and Danielle Branderhorst (Trimbos Institute) for their scrupulous text editing and for care and logistic support during the project, Pat O’Hare and Lucy O’Hare for again taking the job of copy editing (reports on drug problems and policy and on methodological challenges) and Andre Ladenius and his team for desk top publishing. The authors are solely responsible for the views in this book. 3 • 12474-EC boek.indb 3 31-03-2009 09:57:16 • 12474-EC boek.indb 4 31-03-2009 09:57:16 Table of contents - A Report on Global Illicit Drugs Markets 1998-2007 Table of contents Foreword 11 Some highlights from the report 13 Key findings 15 Operation of the world drugs market 15 Production 15 Consumption 15 Revenues 16 Drug related problems 17 Policies 17 Policy assessment 19 Conclusions 20 Observations clés 23 Fonctionnement du marché mondial de la drogue 23 Production 23 Consommation 23 Revenus 24 Problèmes liés à la drogue 25 Politiques 25 Évaluation de la politique 28 Conclusions 29 Main Report: Assessing changes in global drug problems, 1998-2007 31 Peter Reuter 1 Introduction and methodology 33 2 Markets and quantities 35 2.1 Operation of the markets 35 2.2 Production 37 2.3 Consumption 40 2.4 Revenues 43 3 Drug related problems 47 3.1 Introduction 47 3.2 Drug related deaths 47 3.3 HIV 48 3.4 Crime 48 3.5 Economic cost estimates 48 4 Policies 51 4.1 Introduction 51 4.2 Prevention 52 4.3 Treatment 52 4.4 Harm reduction 53 4.5 Enforcement 53 5 Policy assessment 57 5.1 Introduction 57 5.2 Unintended consequences 58 5.3 Drug epidemics 59 5.4 Production and trafficking controls 61 5 • 12474-EC boek.indb 5 31-03-2009 09:57:16 Table of contents - A Report on Global Illicit Drugs Markets 1998-2007 5.5 Domestic enforcement 63 5.6 Methodological issues 63 6 Conclusions 65 References 67 Report 1 71 Assessing the operation of the global drug market Peter Reuter Abstract 73 1 Introduction and overview 75 2 Which nations produce and why 77 3 Smuggling 81 4 Immigrants and trafficking in consumer countries 85 5 The organization of the trade 87 5.1 The early U.S. cocaine market 87 5.2 Colombian smuggling organizations 88 5.3 European smuggling 89 5.4 Drug smuggling and legitimate institutions 89 6 Retail markets 91 7 Concluding comments 93 References 95 Report 2 99 Estimating the size of the global drug market: A demand-side approach Beau Kilmer, Rosalie Pacula Abstract 101 1 Introduction 103 2 Methodological issues associated with demand-side estimates 105 3 Cannabis 107 3.1 Calculating total consumption of cannabis 108 3.1.1 Number of users 108 3.1.2 Number of use days 110 3.1.3 Quantity consumed per use day 110 3.1.4 Underreporting 112 3.1.5 Assessing the face validity of these consumption assumptions 112 3.2 Calculating total retail expenditure 112 3.3 Results 114 3.4 Discussion 116 4 Heroin 119 4.1 Prevalence data 119 4.1.1 Quantity consumed 121 4.1.2 Price 121 4.1.3 Purity 121 4.2 Results and discussion 122 5 Cocaine 125 5.1 Europe 125 5.1.1 Number of users 125 5.1.2 Underreporting 126 5.1.3 Heavy versus light users 127 5.1.4 Consumption days for heavy and light users 127 5.1.5 Consumption per use day 127 5.1.6 Price 128 6 • 12474-EC boek.indb 6 31-03-2009 09:57:16 Table of contents - A Report on Global Illicit Drugs Markets 1998-2007 5.2 Cocaine consumption and expenditure in North America 129 5.2.1 United States 129 5.2.2 Canada 130 5.3 Results and discussion 130 6 Amphetamine-type substances 133 6.1 Quantity consumed 134 6.2 Number of users and price 134 6.3 Underreporting 135 6.4 Results 135 6.5 Methamphetamine 138 7 Conclusion 141 Annex 1 Farm-gate and international trade values for cocaine and opiates 143 Annex 2 GDP estimates for 2005 149 Annex 3 Information about other major opiate markets 151 References 153 Report 3 157 Issues in estimating the economic cost of drug abuse in consuming nations Rosalie Liccardo Pacula, Stijn Hoorens, Beau Kilmer, Peter Reuter, Jim Burgdorf, Priscilia Hunt Abstract 159 1 Introduction 161 2 Review of national studies of the cost of drug abuse 163 3 A process for constructing a global estimate of the burden of illicit drug use 167 4 Difficulties in constructing a global estimate: the need for further refinement 171 4.1 Limiting the number of countries considered 171 4.2 A further reduction in the cost elements considered 173 4.2.1 The literature on the association between drug use an non-fatal productivity losses 173 4.2.2 The literature on drugs and crime 173 4.3 Examination of a few indicators for countries with good data collection systems 174 4.3.1 Drug treatment 174 4.3.2 Injection drug use 175 4.3.3 HIV/AIDS 176 4.3.4 Hepatitis C 177 4.3.5 Hepatitis B 177 4.3.6 Problem drug use 177 4.3.7 Drug related deaths 178 4.3.8 Drug related offences 178 5 Determining the unit cost of drug-related harms 179 5.1 Estimates of the lifetime medical cost of HIV infection 179 5.2 Estimates of the lifetime medical cost of hepatitis C 180 5.3 Estimated cost of hepatitis B 181 5.4 The intangible costs of addiction: Euro per QALY 181 5.5 Cost of law enforcement for drug offenses 182 6 Conclusions 185 References 187 7 • 12474-EC boek.indb 7 31-03-2009 09:57:16 Table of contents - A Report on Global Illicit Drugs Markets 1998-2007 Report 4 191 The drugs problem and drug policy, developments between 1998 - 2007 Franz Trautmann, Peter Reuter, André van Gageldonk, Daan van der Gouwe Abstract 193 1 Introduction 195 2 Approach 197 2.1 Selection of countries 197 2.2 Selecting indicators 198 2.3 Data collection by questionnaire 200 3 Discussion of findings 201 3.1 General remarks 201 3.2 Drug problems 202 3.2.1 Supply 202 3.2.2 Consumption (demand) 206 3.2.3 Drug-related harm 209 3.3 Drug policy 212 3.3.1 Supply reduction 215 3.3.2 Demand reduction 219 3.3.3 Harm reduction 223 4 Concluding discussion 227 4.1 Supply and supply reduction 227 4.2 Demand and demand reduction 227 4.3 Harm and harm reduction 228 4.4 General policy issues 229 4.4.1 Harsh on supply – lenient on use 229 4.4.2 Two conflicting long-term aims of drug policy 229 4.4.3 Two driving forces towards harmonisation 229 References 231 Report 5 233 The unintended consequences of drug policies Peter Reuter Abstract 235 1 Introduction 237 2 Definitions 239 3 A taxonomy of mechanisms 241 4 Displacement 245 5 Positive unintended consequences 247 6 Concluding comments 249 References 251 Report 6 253 Methodological challenges André van Gageldonk, Peter Reuter, Franz Trautmann Abstract 255 1 Introduction 257 2 Drug problems 259 2.1 Production 259
Recommended publications
  • Khiron Life Sciences
    12th July 2019 BUY KHIRON LIFE Fair Value CAD4 SCIENCES Share price EUR1.90 Bloomberg / Reuters KHRN CN/KHRN.V Consumer, Brands & Retail Cannabis Bold Ambition Khiron is set up to be a leader in the Latin American medicinal and branded CPG cannabis markets. From its base in Colombia it is spreading out into Mexico, Peru, Chile, Uruguay and Brazil. Supported by a strong team of seasoned entrepreneurs (and a knowledgeable Board that includes former President of Mexico, Vicente Fox), the company is aiming to take a first mover advantage in the medicinal cannabis and CBD- based branded Consumer packaged goods. We initiate the stock with Buy and a fair value of CAD4.0 per share offering a 100% upside. Its position in medically-validated cannabis products is most advanced in Colombia where the company is fully licensed for the cultivation, production, domestic distribution, and international export of both THC and CBD medical cannabis. It is currently preparing the market for its medicinal cannabis products (to be launched in H2 2019) through in-person clinic consultations, medical association alliances, alliances with pharmacies, health insurance and providing physicians with a variety of cannabis education platforms. In order to accelerate the market development and its own market position, the company has already bought the ILANS clinics in Colombia but we expect more to come. The advantage of running its own neuropathic clinic is that it is much easier to educate doctors in the uses of medicinal cannabis and to switch patients towards the use of medicinal cannabis. Meanwhile, the company’s own developed CBD ski- care brand Kuida is leading the efforts in the health & wellness category.
    [Show full text]
  • Medical Cannabis Latin America & Caribbean
    MEDICAL CANNABIS LATIN AMERICA & CARIBBEAN SPECIAL REPORT 17 56 59 72 CULTIVATING BUSINESS PHARMACEUTICAL & MEDICAL SERVICES & TECHNOLOGY EVENTS Progressive, inclusive medical CBD popularity is surging across The medical cannabis industry A robust events industry cannabis policies can have a the continent as regulatory is birthing a range of secondary has grown around the significant social impact regimes jump to legalize it services across the region medical cannabis sector Image: Nader Ahmed, IndicaOnline Contents 1 FROM THE EDITOR’S DESK Managing Director LATAM Han Le Regional Director LATAM Federica Fermo Country Managers Blanca Bañares, Giulia Di Loreto THE BUSINESS YEAR: Country Editors Alejandra Gómez Arreola, Juan Pablo Vásquez Pedraza, Juan Manuel Mejía Salazar, Enrique José García, MEDICAL CANNABIS Daniel Alarcón Project Assistant LATIN AMERICA Angie Serrato Chief Executive Officer Ayşe Hazır Valentin Editor-in-Chief & CARIBBEAN Peter Howson Senior Editor Terry Whitlam Writer/Editor SPECIAL REPORT Evan Pheiffer Associate Editor Liz Colavita Chief Sub-Editor Shireen Nisha Sub-Editors Kabir Ahmad, Alia Kıran Editorial Coordinator Belemir Ece Çolak Web Editor Aidan McMahon Web Assistant & Social Media Coordinator Ahsen Durukan Web Developer Volkan Görmüş Assistant Web Developer Zişan Yalçınkaya Analytics Assistant Sena Özcanlı Art Director Emily Zier-Ünlü Junior Art Director Emre Boduç Senior Motion Graphic Designer Serkan Yıldırım he Business Year’s Special Report on market, and as the ideal exporter to its neigh- Motion Graphic Designer Medical Cannabis in Latin America bor and largest cannabis (medical or other- Yiğit Yeşillik T Senior Graphic Designers and the Caribbean is the second entry wise) market, the US, but has yet to clear the fi- Bilge Saka, Şule Kocakavak in our medical cannabis series, building upon nal obstacles in the country’s legal process and Contributors our inaugural report on the Colombian market.
    [Show full text]
  • Cannabis in Mexico Report How Big? How Far? How Fast?
    Cannabis in Mexico Report How Big? How Far? How Fast? Inaugural Edition – October 2019 Regulation of the legal production, sale and use of cannabis in Mexico is advancing at a strong and steady pace. Although the precise timeline and legal framework remain to be seen, interested parties are exploring ways to participate appropriately in a market of approximately 130 million people. Once banned and subject to stringent enforcement, cannabis and its derivatives, supported by strong science (R&D) and innovation, are rapidly becoming mainstream products across North America. In the United States, while the possession and use of cannabis remains a federal offense, two-thirds of the individual states already permit the medicinal use of cannabis while eleven have now legalized cannabis for recreational use and active consideration of such legalization is underway in others.1 At the federal level, hemp has been removed from the Schedule I controlled substances list, making it an ordinary agricultural commodity (with regulations still being developed by USDA), allowing for rapid development of a new market in CBD-related products. Canada nationally authorized medicinal use of cannabis in 2001 and recreational use in 2018. In Mexico, the Supreme Court has ruled in favor of access for personal use, and the administration of President Andrés Manuel López Obrador (AMLO) has indicated it also favors comprehensive regulation of cannabis use and consumption as part of its strategy to 1 Cannabis is still classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency, and, as such, it remains a federal crime in the United States to grow, sell, possess, distribute and/or use cannabis, regardless of any U.S.
    [Show full text]
  • Science, Ideological Dialectics, and Predicted Flows from Latin America
    DOI: 10.26717/BJSTR.2018.05.001154 Ki-Hoon Jun. Biomed J Sci & Tech Res ISSN: 2574-1241 Review Article Open Access Marijuana in the US -Science, Ideological Dialectics, and predicted flows from Latin America Ki Hoon Jun* Graduate School Latin American Studies, Hankuk University of Foreign Studies, South Korea Received: May 20, 2018; Published: May 31, 2018 *Corresponding author: Ki-Hoon Jun, Graduate School Latin American Studies, Hankuk University of Foreign Studies, South Korea Abstract Counter-intuititvely, it is socio-historical, geographic traits, and natural conditions which led to marijuana’s stigmization as drug. Besides, its stigmization in U.S. is rather related with racialorign of its introduction; it was first brought by black slaves and Mexican refugees fleeing from Mexico Revolution in 1910. Despite previous prevalence of its consumption over tobacco, since 1920s the white’s racist fear and ant sentiments led to its prohibition. However, since late-2000s scientists began revealing that marijuana’s defects had been hitherto exaggerated and that its harm is even less than that of alcohol-drink. Besides, the racist origin of marijuana prohibition lately came into light, suppressing any anti- marijuana stance as a strong ideological tool. As a result, by 2016 more than a half of Americans consume or have consumed marijuana. And anti-racist appeal against marijuana-restriction is serving as a strong ideological and moraalistic apparatus to suppress any further warning against marijuana-overdose or over-diffusion. But while it’s soaring demand is hardly met by domestic production, which is feasible only in California for natural condition. Then the majority should come from Latin American imports.
    [Show full text]
  • Cultura Y Droga (Año 22 No. 24 Ene-Dic 2017) Titulo Tanan, Cauê
    Cultura y droga (Año 22 no. 24 ene-dic 2017) Titulo Tanan, Cauê - Autor/a; Apud-Peláez, Ismael Eduardo - Autor/a; Ramos-Gómez, Autor(es) Oliver - Autor/a; Olvera-Hernández, Nidia Andrea - Autor/a; Schievenini Stefanoni, José Domingo - Autor/a; Muñoz Mendoza, Joaquín - Autor/a; Borja-Martínez, Ramiro E. - Autor/a; Góngora Sierra, Andrés L. - Autor/a; Sánchez-González, Carlos - Autor/a; Correa-Lagos, Carlos Enrique - Autor/a; Manizales Lugar Universidad de Caldas Editorial/Editor 2017 Fecha Colección Psicología; Antropología; Indígenas; Chamanismo; Consumo de drogas; España; Temas Brasil; Colombia; México; Revista Tipo de documento "http://biblioteca.clacso.edu.ar/Colombia/juridicasysoc-uc/20190409012407/24.pdf" URL Reconocimiento CC BY Licencia http://creativecommons.org/licenses/by-nc-nd/2.0/deed.es Segui buscando en la Red de Bibliotecas Virtuales de CLACSO http://biblioteca.clacso.edu.ar Consejo Latinoamericano de Ciencias Sociales (CLACSO) Conselho Latino-americano de Ciências Sociais (CLACSO) Latin American Council of Social Sciences (CLACSO) www.clacso.edu.ar ISSN: 0122-8455 (Impreso) cult.drog. Manizales - Colombia Año 22 No. 24 172 p. enero-diciembre 2017 ISSN: 2590-7840 (En línea) UNIVERSIDAD DE CALDAS Universidad de Montevideo Josep María Fericgla González ISSN: 0122-8455 (Impreso) Antropólogo, Ph.D. ISSN: 2590-7840 (En línea) Universidad de Barcelona Fundada en 1993 Jorge Ronderos Valderrama Periodicidad Anual Sociólogo, Ph.D. Tiraje 300 ejemplares Universidad de Sevilla Año 22 No. 24, 172 p. Jim A. Bauml enero-diciembre, 2017 Biologist, P.h.D. Manizales - Colombia Angeles Arboretum and hedonic Golden Luis Miguel Alvarez Ingeniero Agronómo Rector Universidad de Caldas Universidad de Caldas Beatriz Acevedo Holguín Felipe César Londoño López Sistemas y Gerencia, Ph.D.
    [Show full text]
  • International Law and Drug Policy Reform
    INTERNATIONAL LAW AND DRUG POLICY REFORM Report of a GDPO/ICHRDP/TNI/WOLA Expert Seminar Washington, D.C. 17–18 October 2014 Drug policy reform is currently higher on the international agenda than it has been in recent memory. With a United Nations General Assembly Special Session (UNGASS) on drugs set for 19-21 April 2016, the prominence of this issue will further increase. Significant legal and policy reforms at the national level have taken place in recent years that pose considerable challenges to the international legal framework for drug control, and beg important questions regarding states’ international legal obligations. As these debates move forward and as such reforms expand, international drug control law, often regarded as distant and arcane, becomes a more immediate and tangible concern. Clear legal tensions and, in some cases, breaches, are evident. The responses to these challenges will have ramifications beyond national borders and into international relations, and beyond international drug control law and into the broader realm of public international law. The Expert Seminar “International Law and Drug Policy Reform,” organized by The Global Drug Policy Observatory (GDPO), International Centre on Human Rights and Drug Policy (ICHRDP), Transnational Institute (TNI) and the Washington Office on Latin America (WOLA), took place in Washington, D.C., on 17-18 October 2014. The meeting convened international legal scholars from academia, the United Na- tions, and governmental agencies to discuss and debate international legal challenges and dilemmas raised by ongoing drug policy developments. It marked the first phase of an ongoing collaboration be- tween the host organizations intended to inform a fluid and fast-moving debate with robust interna- tional legal analysis.
    [Show full text]
  • Human Security and Crime in Latin America: the Political Capital and Political Impact of Criminal Groups and Belligerents Involved in Illicit Economies
    Human Security and Crime in Latin America: The Political Capital and Political Impact of Criminal Groups and Belligerents Involved in Illicit Economies Vanda Felbab-Brown The Brookings Institution September 2011 APPLIED RESEARCH CENTER FLORIDA INTERNATIONAL UNIVERSITY THE WESTERN HEMISPHERIC SECURITY ANALYSIS CENTER WHEMSAC brings together a versatile and important Latin American network of traditional and non-traditional security experts from academia, business sectors, government ministries and private organizations. Its research capabilities provide Western Hemispheric leaders with a unique, real-time research and analysis on current issues. WHEMSAC is an innovative institutional model for conducting professional qualitative and quantitative research throughout the Americas at the national, regional and international levels within an open, independent, multi-disciplinary, and collaborative academic environment. The fusion of open source political, economic, and social expertise allows WHEMSAC to provide an exceptional, qualified approach to regional security insight with traditional intra-governmental analysis. WESTERN HEMISPHERIC SECURITY ANALYSIS CENTER SPONSORS The Applied Research Center advances the research and academic mission of Florida International University. ARC‟s focus is to solve real-world problems through multi-disciplinary research collaborations within the University's increasingly talented applied and basic research units. It is uniquely structured and staffed to allow for free-flowing exchange of ideas between the
    [Show full text]
  • Cannabis in Mexico an Open Debate
    IDPC Briefing Paper Cannabis in Mexico an open debate Jorge Hernández Tinajero1 August 2010 Leopoldo Rivera Rivera2 The International Drug Policy Consortium (IDPC) is a global network of NGOs and professional networks that specialise in issues related to illegal drug production and use. The Consortium aims to promote objective and open debate on the effectiveness, direction and content of drug policies at national and international level, and supports evidence-based policies that are effective in reducing drug-related harm. It produces occasional briefing papers, disseminates the reports of its member organisations about particular drug-related matters, and offers expert consultancy services to policy makers and officials around the world. Introduction Historical perspective on illicit drugs in Mexico n August 2010, before a meeting of Iacademics and representatives of civil The history of cannabis in Mexico, while not as society organisations, Mexican President Felipe ancient as in other regions of the world, can Calderón declared that the legalisation of illicit be traced back to five centuries. The cannabis drugs could contribute to reducing the power plant has been constantly present in Mexican held by organised crime. He quickly added, society, economy and culture, since it was however, that this was not an option that would introduced by the Spaniards in the 16th century, be considered by his own administration. His either in the form of products fashioned from statements unleashed a series of comments the hemp, for traditional medicinal purposes, or from politicians, the media and many sectors as a psychoactive substance. of Mexican society that had until then remained silent.
    [Show full text]
  • Gootenberg Review
    Vol. 13, No. 1, Fall 2015, 341-348 Review/Reseña Elaine Carey, Women Drug Traffickers: Mules, Bosses & Organized Crime. Albuquerque: University of New Mexico Press, 2014. Diálogos Series. Hustlin’ with some Transnational Women (and the Emerging Drug History of Mexico) Paul Gootenberg Stony Brook University You gotta love a scholarly book—and this is definitely one—that cites a documentary called Cocaine Cowboys 2: Hustlin’ with the Godmother as a primary source (183). Elaine Carey’s new book, which retrieves the careers of a trail of iconic and colorful female drug traffickers in the twentieth century, breaks new ground in the drug history of Mexico and Latin America, transnational border studies, and women and gender studies. It’s also a tale well told that may capture a general audience beyond the usual academic suspects. Recent events—the dramatic post-1980s swell of Mexican drug trafficking networks to the United States, and now the brutal explosion of drug violence after 2006 (as the Mexican state and northern traffickers Gootenberg 342 unleashed a no-holds bared drug war) have revealed how little real historical research exists on drug trades in Mexico. The escapades and escapes of figures like Joaquín “El Chapo” Guzmán, putative head of the Sinaloan cartel (a term specialists abhor), only reinforce this loud macho big bad guy vs. bad guy or state narrative. Illicit invisible activities, of course, are specially challenging for serious historical research and must lean heavily on policing records with all their predictable biases and gaps. We are vaguely familiar with a long string of historic drug smuggling and vice trades since the early 1900s across the U.S-Mexican border and its growing border towns: newly-proscribed patent medicines and pharmaceuticals in the teens, millions of gallons of booze during 1920s Prohibition, Mexican made brown heroin from the 1940s and beyond, marijuana from the 1930s to 1960s.
    [Show full text]
  • Legal Penalty for Consuming Cannabis in Morocco
    Legal Penalty For Consuming Cannabis In Morocco herIs Mischa coracle heavy fiftieth or evangelized exogenous andafter practise cup-tied tiresomely. Garvey inlace Maury so noddingly?character senatorially. Incog and rhombic Artie jump Download Legal Penalty For Consuming Cannabis In Morocco pdf. Download Legal Penalty For gasesConsuming that is Cannabis produced In nationwide, Morocco doc. and Meant drug for major any cannabisdefinition legalof cannabis cannabis is it,morocco which the and offense? emit harmful usualCharged penalty with legalfor cannabis penalty moroccofor cannabis to learn in morocco how are and some conditions states? Unlessand politics there in. was Registered the legal inpenalty the containsfor cannabis the law.morocco Vape and or buyingshe also it legalwidely penalty tolerated consuming but uruguay cannabis is a plant morocco produces and start poisonous here are and thancommitting the legal a firearm penalty and for consumingsprinkling and cannabis other similar in the cannabisnotice and consumption consumption. are Psychotropic conservative substances when you cannabislike to clearly tolerance mark anyvaries business according to cannabis? to its effects Hands of the of differencethe usual penaltybetween cannabis morocco in and possession conditions of anotherand a dispensary. private and Refrained targeted ifads user are is there. legal forLegislative consuming session cannabis in the in usual a reality penalty in private for consuming parties or cannabis legalizationmorocco and of she larger suffers amounts from ofnative letters and may driving? not be. Tunisians Bitcoin accepted have legal by penalty the usual consuming penalty for thatconsuming people cannabiswalking down in michigan? and use Differsor a website. in your Did cannabis than traditional legal for consuminguse legal penalty in morocco for consuming to a callback court.cannabis Cactus outside in morocco of penalties.
    [Show full text]
  • March 26, 2019 MEXICO CANNABIS UPDATE #4 Status of Proposed
    March 26, 2019 MEXICO CANNABIS UPDATE #4 Status of Proposed and ExistinG ReGulation COFEPRIS Guidelines On March 19, 2019, the Secretariat of Health issued a press release informing the appearance of Secy. Jorge Alcocer before the Senate’s Health Committee to discuss the nation’s public health agenda. Among the top items was the status on the guidelines issued on October 30, 2018 by the Federal Commission for the Protection of Sanitary Risks (“COFEPRIS”) for the import and sale of products with cannabis and its derivates (reported here). Since the guidelines were issued, two batches of products were authorized and announced in highly publicized press conferences. This was pretty much everything the agency got to do before the new president was elected and the new administration officers took over government agencies such as COFEPRIS. The permits were issued but claims have been made that COFEPRIS purportedly has not completed the process granting the final permit to import the authorized products. We inquired with current and former COFEPRIS employees regarding status of current applications and all responses mentioned in one way or another that an instruction was given to halt review of all applications and look into any signs of irregular activity. On the other hand, Secy. Alcocer informed the Senate during the aforementioned appearance that the COFEPRIS guidelines would be “substituted” with a new set of rules to be issued jointly by the Secretary of Health and the Secretary of the Interior. Mr. Alcocer stated that the current guidelines are “lax and limited” and cause serious concerns regarding potential ability of minors to unrestricted access cannabis products, among others.
    [Show full text]
  • Download Program
    Time DAY 1 8 am - 4 pm Registration 8:15 am - 9 am Coffee Break 9 am - 9:20 am Opening anD Welcome Keynote Speaker Julieta Lemaitre Ripoll, 9:20 am - 10:20 am 'The Peace at HanD: Global Prohibition anD the Impossibility of Peace in Colombia' 10:20 am - 10:40 am BREAK PANEL 4: New theoretical 10:40 am - 12:10 pm PANEL 1: Drug enforcement: PANEL 3: Narratives anD anD methoDological PANEL 2: Policing prohibition SESSION 1 Past, present anD future perceptions of drug market approaches to Drug dependence and treatment Room TBA TBA TBA TBA Chair TBA TBA TBA TBA The National Policy of counter (Un)bounded authority: the What can we learn from users' The High Five Club: HIV Risk Narcotics for post-peace in limits and uses of police knowledge and involvement Perception, Stigma and Afghanistan. Khaja authority in encounters with in illicit drug markets? A Defiance in West Virginia, Humayoun Amini young people who use drugs comparative study of 37 users United States. Jeff Ondocsin from British Columbia, of opioids, stimulants and Canada. Alissa Greer cannabinoids. Ashely Granville The law enforcement costs of Narratives of Drug Supply in Practices of care among Migrants, refugees and de facto 'criminalizing' drug Iran: Violence, Drug Policy, people who buy, use and sell ethnic minorities: an possession: Lessons from Italy. and Drug Control. Alexander drugs in community settings. overview of responses to Davide Fortin Soderholm Gillian Kolla drug-related issues in Europe. Charlotte De Kock Enforcement Strategies for Is police the problem? Law Drug buyers and dealers: How Remaking the Angry Fentanyl and Other Synthetic enforcement, symbolic social relations mediate trust Narcanned Subject: Opioids; Can we learn from violence and street-level drug at the point of purchase.
    [Show full text]